Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models

Stem Cell Research

Volumn 12, Issue 1, 2014, Pages 36-48

  Yi, Bo Rim ^a   Hwang, Kyung A ^a   Aboody, Karen S ^b   Jeung, Eui Bae ^a   Kim, Seung U ^c,d   Choi, Kyung Chul ^a  

^a Chungbuk National University   (South Korea)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Chung Ang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; CYTOSINE DEAMINASE; FLUOROURACIL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CELL SELECTION; CELL STRAIN MCF 7; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG EFFICACY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LONG TERM SURVIVAL; MOUSE; NEURAL STEM CELL; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CELL- AND TISSUE-BASED THERAPY; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-BETA; MCF-7 CELLS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEURAL STEM CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84885965181     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2013.09.010     Document Type: Article

References (50)

1. Aboody K.S., Bush R.A., Garcia E., Metz M.Z., Najbauer J., Justus K.A., Phelps D.A., Remack J.S., Yoon K.J., Gillespie S., Kim S.U., Glackin C.A., Potter P.M., Danks M.K. Development of a tumor-selective approach to treat metastatic cancer. PLoS One 2006, 1:e23.
2. Aboody K.S., Najbauer J., Danks M.K. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008, 15:739-752.
3. Aboody K., Capela A., Niazi N., Stern J.H., Temple S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta Stone. Neuron 2011, 70:597-613.
4. Anderson W.F. Gene therapy scores against cancer. Nat. Med. 2000, 6:862-863.
5. Bevers T.B., Anderson B.O., Bonaccio E., Buys S., Daly M.B., Dempsey P.J., Farrar W.B., Fleming I., Garber J.E., Harris R.E., Heerdt A.S., Helvie M., Huff J.G., Khakpour N., Khan S.A., Krontiras H., Lyman G., Rafferty E., Shaw S., Smith M.L., Tsangaris T.N., Williams C., Yankeelov T. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J. Natl. Compr. Cancer Netw. 2009, 7:1060-1096.
6. Conrad C., Husemann Y., Niess H., von Luettichau I., Huss R., Bauer C., Jauch K.W., Klein C.A., Bruns C., Nelson P.J. Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1-induced differentiation to target cancer angiogenesis. Ann. Surg. 2011, 253:566-571.
7. Danks M.K., Yoon K.J., Bush R.A., Remack J.S., Wierdl M., Tsurkan L., Kim S.U., Garcia E., Metz M.Z., Najbauer J., Potter P.M., Aboody K.S. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res. 2007, 67:22-25.
8. Day J.C., Tisi L.C., Bailey M.J. Evolution of beetle bioluminescence: the origin of beetle luciferin. Luminescence 2004, 19:8-20.
9. Di Domenico M., Ricciardi C., Fusco A., Pierantoni G.M. Anti-VEGF therapy in breast and lung mouse models of cancers. J. Biomed. Biotechnol. 2010, 2011:947928.
10. El Haddad N., Heathcote D., Moore R., Yang S., Azzi J., Mfarrej B., Atkinson M., Sayegh M.H., Lee J.S., Ashton-Rickardt P.G., Abdi R. Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood 2011, 117:1176-1183.
11. Fuchita M., Ardiani A., Zhao L., Serve K., Stoddard B.L., Black M.E. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res. 2009, 69:4791-4799.
12. Hernandez-Alcoceba R., Sangro B., Prieto J. Gene therapy of liver cancer. World J. Gastroenterol. 2006, 12:6085-6097.
13. Kang N.H., Hwang K.A., Kim S.U., Kim Y.B., Hyun S.H., Jeung E.B., Choi K.C. Potential antitumor therapeutic strategies of human amniotic membrane and amniotic fluid-derived stem cells. Cancer Gene Ther. 2012, 19:517-522.
14. Kang N.H., Hwang K.A., Yi B.R., Lee H.J., Jeung E.B., Kim S.U., Choi K.C. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models. Cancer Gene Ther. 2012, 19:412-419.
15. Kang N.H., Lee W.K., Yi B.R., Park M.A., Lee H.R., Park S.K., Hwang K.A., Park H.K., Choi K.C. Modulation of lipid metabolism by mixtures of protamine and chitooligosaccharide through pancreatic lipase inhibitory activity in a rat model. Lab. Anim. Res. 2012, 28:31-38.
16. Kang N.H., Yi B.R., Lim S.Y., Hwang K.A., Baek Y.S., Kang K.S., Choi K.C. Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB/c female nude mice bearing disseminated breast cancer xenografts. Int. J. Oncol. 2012, 40:2022-2028.
17. Kim S.U., Nakagawa E., Hatori K., Nagai A., Lee M.A., Bang J.H. Production of immortalized human neural crest stem cells. Methods Mol. Biol. 2002, 198:55-65.
18. Kim S.K., Kim S.U., Park I.H., Bang J.H., Aboody K.S., Wang K.C., Cho B.K., Kim M., Menon L.G., Black P.M., Carroll R.S. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin. Cancer Res. 2006, 12:5550-5556.
19. Kim S.U., Park I.H., Kim T.H., Kim K.S., Choi H.B., Hong S.H., Bang J.H., Lee M.A., Joo I.S., Lee C.S., Kim Y.S. Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology 2006, 26:129-140.
20. Kim K.Y., Kim S.U., Leung P.C., Jeung E.B., Choi K.C. Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci. 2010, 101:955-962.
21. Lee D.H., Ahn Y., Kim S.U., Wang K.C., Cho B.K., Phi J.H., Park I.H., Black P.M., Carroll R.S., Lee J., Kim S.K. Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin. Cancer Res. 2009, 15:4925-4934.
22. Lim L.Y., Vidnovic N., Ellisen L.W., Leong C.O. Mutant p53 mediates survival of breast cancer cells. Br. J. Cancer 2009, 101:1606-1612.
23. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
24. Lv H., Pan G., Zheng G., Wu X., Ren H., Liu Y., Wen J. Expression and functions of the repressor element 1 (RE-1)-silencing transcription factor (REST) in breast cancer. J. Cell. Biochem. 2010, 110:968-974.
25. Lynch H.T., Silva E., Snyder C., Lynch J.F. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J. 2008, 14:3-13.
26. Matsuzuka T., Rachakatla R.S., Doi C., Maurya D.K., Ohta N., Kawabata A., Pyle M.M., Pickel L., Reischman J., Marini F., Troyer D., Tamura M. Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer 2009, 70:28-36.
27. McArthur H.L., Mahoney K.M., Morris P.G., Patil S., Jacks L.M., Howard J., Norton L., Hudis C.A. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 2011, 117:5461-5468.
28. Nawa A., Tanino T., Luo C., Iwaki M., Kajiyama H., Shibata K., Yamamoto E., Ino K., Nishiyama Y., Kikkawa F. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?. Anti Cancer Agents Med. Chem. 2008, 8:232-239.
29. Niess H., Bao Q., Conrad C., Zischek C., Notohamiprodjo M., Schwab F., Schwarz B., Huss R., Jauch K.W., Nelson P.J., Bruns C.J. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann. Surg. 2011, 254:767-774. (discussion 774-765).
30. Oie S., Ono M., Yano H., Maruyama Y., Terada T., Yamada Y., Ueno T., Kojiro M., Hirano K., Kuwano M. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. Int. J. Oncol. 2006, 29:1469-1478.
31. Pastorakova A., Hlubinova K., Altaner C. Treatment of human tumor cells by combine gene therapy harnessing plasmids expressing human tumor necrosis factor alpha and bacterial cytosine deaminase suicide gene. Neoplasma 2006, 53:478-484.
32. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
33. Piccart M. The role of taxanes in the adjuvant treatment of early stage breast cancer. Breast Cancer Res. Treat. 2003, 79(Suppl. 1):S25-S34.
34. Qiao J., Black M.E., Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum. Gene Ther. 2000, 11:1569-1576.
35. Rosewicz S., Detjen K., Scholz A., von Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004, 80(Suppl. 1):85-93.
36. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Deliv. Rev. 2012, 64:739-748.
37. Sottini A., Capra R., Serana F., Chiarini M., Caimi L., Imberti L. Interferon-beta therapy monitoring in multiple sclerosis patients. Endocrinol. Metab. Immune Disord. Drug Targets 2009, 9:14-28.
38. Thu M.S., Najbauer J., Kendall S.E., Harutyunyan I., Sangalang N., Gutova M., Metz M.Z., Garcia E., Frank R.T., Kim S.U., Moats R.A., Aboody K.S. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS One 2009, 4:e7218.
39. Uze G., Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007, 89:729-734.
40. Vincent-Salomon A., Thiery J.P. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 2003, 5:101-106.
41. Vogel K.J., Atchley D.P., Erlichman J., Broglio K.R., Ready K.J., Valero V., Amos C.I., Hortobagyi G.N., Lu K.H., Arun B. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J. Clin. Oncol. 2007, 25:4635-4641.
42. Volate S., Hudson R., Wang D., Muga S., Wargovich M. TJ-41 induces apoptosis and potentiates the apoptotic effects of 5-FU in breast cancer cell lines. J. Oncol. 2009, 2009:895381.
43. Wagner T.C., Velichko S., Chesney S.K., Biroc S., Harde D., Vogel D., Croze E. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int. J. Cancer 2004, 111:32-42.
44. Wallace J.A., Li F., Leone G., Ostrowski M.C. Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. Cancer Res. 2011, 71:1203-1207.
45. Yi B.R., Kang N.H., Hwang K.A., Kim S.U., Jeung E.B., Choi K.C. Antitumor therapeutic effects of cytosine deaminase and interferon-{beta} against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res. 2011, 31:2853-2861.
46. Yi B.R., O S.N., Kang N.H., Hwang K.A., Kim S.U., Jeung E.B., Kim Y.B., Heo G.J., Choi K.C. Genetically engineered stem cells expressing cytosine deaminase and interferon-beta migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects. Int. J. Oncol. 2011, 39:833-839.
47. Yi B.R., Hwang K.A., Kang N.H., Kim S.U., Jeung E.B., Kim H.C., Choi K.C. Synergistic effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta via their tumor tropism to selectively target human hepatocarcinoma cells. Cancer Gene Ther. 2012, 19:644-651.
48. Yoshiji H., Kuriyama S., Noguchi R., Yoshii J., Ikenaka Y., Yanase K., Namisaki T., Kitade M., Yamazaki M., Tsujinoue H., Fukui H. Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development. Liver Int. 2005, 25:153-161.
49. Zhao D., Najbauer J., Annala A.J., Garcia E., Metz M.Z., Gutova M., Polewski M.D., Gilchrist M., Glackin C.A., Kim S.U., Aboody K.S. Human neural stem cell tropism to metastatic breast cancer. Stem Cells 2012, 30:314-325.
50. Zoli W., Ulivi P., Tesei A., Fabbri F., Rosetti M., Maltoni R., Giunchi D.C., Ricotti L., Brigliadori G., Vannini I., Amadori D. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res. 2005, 7:R681-R689.